Hologic study shows benefits of Low Dose 3D Mammography system

Hologic has announced the publication of new study results showing the benefits its Low Dose 3D Mammography system offers in the detection of invasive cancers.

Published in The Lancet, the study demonstrated how Genius 3D Mammography exams carried out with the machine offered advantages over 2D mammography alone.

The results of mammography exams were analysed for 9,677 women, all of whom were asymptomatic and over the age of 49. It was shown that breast tomosynthesis screening exams with conventional 2D detected 35 percent more cancers and 76 percent more invasive cancers when compared to 2D mammography alone.

Furthermore, the combination of breast tomosynthesis with C-View 2D images detected 40 percent more cancers overall and 83 percent more invasive cancers than 2D mammography techniques used on their own.

This marks the first prospective study publishing final results confirming the benefit each screening modality has on invasive cancer detection rates compared to traditional techniques.

Pete Valenti, Hologic's division president for breast and skeletal health solutions, said: "We've received very positive feedback from customers who have embraced the technology, and this prospective study further confirms that Genius 3D Mammography exams maintain the same outstanding performance when coupled with C-View software."

With over 20 years of experience within the science market, we at Zenopa have the knowledge skill and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.